MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression

Jessica L. Christenson, Kiel T. Butterfield, Nicole S. Spoelstra, John D. Norris, Jatinder S. Josan, Julie A. Pollock, Donald P. McDonnell, Benita S. Katzenellenbogen, John A. Katzenellenbogen, Jennifer K. Richer

Research output: Contribution to journalArticle

Abstract

Triple-negative breast cancer (TNBC) has a faster rate of metastasis compared to other breast cancer subtypes, and no effective targeted therapies are currently FDA-approved. Recent data indicate that the androgen receptor (AR) promotes tumor survival and may serve as a potential therapeutic target in TNBC. Studies of AR in disease progression and the systemic effects of anti-androgens have been hindered by the lack of an AR-positive (AR+) immunocompetent preclinical model. In this study, we identified the transgenic MMTV-PyMT (mouse mammary tumor virus-polyoma middle tumor-antigen) mouse mammary gland carcinoma model of breast cancer and Met-1 cells derived from this model as tools to study the role of AR in breast cancer progression. AR protein expression was examined in late-stage primary tumors and lung metastases from MMTV-PyMT mice as well as in Met-1 cells by immunohistochemistry (IHC). Sensitivity of Met-1 cells to the AR agonist dihydrotestosterone (DHT) and anti-androgen therapy was examined using cell viability, migration/invasion, and anchorage-independent growth assays. Late-stage primary tumors and lung metastases from MMTV-PyMT mice and Met-1 cells expressed abundant nuclear AR protein, while negative for estrogen and progesterone receptors. Met-1 sensitivity to DHT and AR antagonists demonstrated a reliance on AR for survival, and AR antagonists inhibited invasion and anchorage-independent growth. These data suggest that the MMTV-PyMT model and Met-1 cells may serve as valuable tools for mechanistic studies of the role of AR in disease progression and how anti-androgens affect the tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)69-77
Number of pages9
JournalHormones and Cancer
Volume8
Issue number2
DOIs
StatePublished - Apr 1 2017

Fingerprint

Triple Negative Breast Neoplasms
Mouse mammary tumor virus
Androgen Receptors
Neoplasm Antigens
Breast Neoplasms
Androgens
Androgen Receptor Antagonists
Neoplasm Metastasis
Disease Progression
Neoplasms
Lung
Tumor Microenvironment
Dihydrotestosterone
Progesterone Receptors
Human Mammary Glands
Cytoplasmic and Nuclear Receptors
Growth
Estrogen Receptors
Transgenic Mice
Cell Movement

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Cancer Research

Cite this

Christenson, J. L., Butterfield, K. T., Spoelstra, N. S., Norris, J. D., Josan, J. S., Pollock, J. A., ... Richer, J. K. (2017). MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. Hormones and Cancer, 8(2), 69-77. https://doi.org/10.1007/s12672-017-0285-6

MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. / Christenson, Jessica L.; Butterfield, Kiel T.; Spoelstra, Nicole S.; Norris, John D.; Josan, Jatinder S.; Pollock, Julie A.; McDonnell, Donald P.; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.; Richer, Jennifer K.

In: Hormones and Cancer, Vol. 8, No. 2, 01.04.2017, p. 69-77.

Research output: Contribution to journalArticle

Christenson, JL, Butterfield, KT, Spoelstra, NS, Norris, JD, Josan, JS, Pollock, JA, McDonnell, DP, Katzenellenbogen, BS, Katzenellenbogen, JA & Richer, JK 2017, 'MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression', Hormones and Cancer, vol. 8, no. 2, pp. 69-77. https://doi.org/10.1007/s12672-017-0285-6
Christenson, Jessica L. ; Butterfield, Kiel T. ; Spoelstra, Nicole S. ; Norris, John D. ; Josan, Jatinder S. ; Pollock, Julie A. ; McDonnell, Donald P. ; Katzenellenbogen, Benita S. ; Katzenellenbogen, John A. ; Richer, Jennifer K. / MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. In: Hormones and Cancer. 2017 ; Vol. 8, No. 2. pp. 69-77.
@article{0e3384e09c364b9f9a52c57db6f78a33,
title = "MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression",
abstract = "Triple-negative breast cancer (TNBC) has a faster rate of metastasis compared to other breast cancer subtypes, and no effective targeted therapies are currently FDA-approved. Recent data indicate that the androgen receptor (AR) promotes tumor survival and may serve as a potential therapeutic target in TNBC. Studies of AR in disease progression and the systemic effects of anti-androgens have been hindered by the lack of an AR-positive (AR+) immunocompetent preclinical model. In this study, we identified the transgenic MMTV-PyMT (mouse mammary tumor virus-polyoma middle tumor-antigen) mouse mammary gland carcinoma model of breast cancer and Met-1 cells derived from this model as tools to study the role of AR in breast cancer progression. AR protein expression was examined in late-stage primary tumors and lung metastases from MMTV-PyMT mice as well as in Met-1 cells by immunohistochemistry (IHC). Sensitivity of Met-1 cells to the AR agonist dihydrotestosterone (DHT) and anti-androgen therapy was examined using cell viability, migration/invasion, and anchorage-independent growth assays. Late-stage primary tumors and lung metastases from MMTV-PyMT mice and Met-1 cells expressed abundant nuclear AR protein, while negative for estrogen and progesterone receptors. Met-1 sensitivity to DHT and AR antagonists demonstrated a reliance on AR for survival, and AR antagonists inhibited invasion and anchorage-independent growth. These data suggest that the MMTV-PyMT model and Met-1 cells may serve as valuable tools for mechanistic studies of the role of AR in disease progression and how anti-androgens affect the tumor microenvironment.",
author = "Christenson, {Jessica L.} and Butterfield, {Kiel T.} and Spoelstra, {Nicole S.} and Norris, {John D.} and Josan, {Jatinder S.} and Pollock, {Julie A.} and McDonnell, {Donald P.} and Katzenellenbogen, {Benita S.} and Katzenellenbogen, {John A.} and Richer, {Jennifer K.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s12672-017-0285-6",
language = "English (US)",
volume = "8",
pages = "69--77",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",
number = "2",

}

TY - JOUR

T1 - MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression

AU - Christenson, Jessica L.

AU - Butterfield, Kiel T.

AU - Spoelstra, Nicole S.

AU - Norris, John D.

AU - Josan, Jatinder S.

AU - Pollock, Julie A.

AU - McDonnell, Donald P.

AU - Katzenellenbogen, Benita S.

AU - Katzenellenbogen, John A.

AU - Richer, Jennifer K.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Triple-negative breast cancer (TNBC) has a faster rate of metastasis compared to other breast cancer subtypes, and no effective targeted therapies are currently FDA-approved. Recent data indicate that the androgen receptor (AR) promotes tumor survival and may serve as a potential therapeutic target in TNBC. Studies of AR in disease progression and the systemic effects of anti-androgens have been hindered by the lack of an AR-positive (AR+) immunocompetent preclinical model. In this study, we identified the transgenic MMTV-PyMT (mouse mammary tumor virus-polyoma middle tumor-antigen) mouse mammary gland carcinoma model of breast cancer and Met-1 cells derived from this model as tools to study the role of AR in breast cancer progression. AR protein expression was examined in late-stage primary tumors and lung metastases from MMTV-PyMT mice as well as in Met-1 cells by immunohistochemistry (IHC). Sensitivity of Met-1 cells to the AR agonist dihydrotestosterone (DHT) and anti-androgen therapy was examined using cell viability, migration/invasion, and anchorage-independent growth assays. Late-stage primary tumors and lung metastases from MMTV-PyMT mice and Met-1 cells expressed abundant nuclear AR protein, while negative for estrogen and progesterone receptors. Met-1 sensitivity to DHT and AR antagonists demonstrated a reliance on AR for survival, and AR antagonists inhibited invasion and anchorage-independent growth. These data suggest that the MMTV-PyMT model and Met-1 cells may serve as valuable tools for mechanistic studies of the role of AR in disease progression and how anti-androgens affect the tumor microenvironment.

AB - Triple-negative breast cancer (TNBC) has a faster rate of metastasis compared to other breast cancer subtypes, and no effective targeted therapies are currently FDA-approved. Recent data indicate that the androgen receptor (AR) promotes tumor survival and may serve as a potential therapeutic target in TNBC. Studies of AR in disease progression and the systemic effects of anti-androgens have been hindered by the lack of an AR-positive (AR+) immunocompetent preclinical model. In this study, we identified the transgenic MMTV-PyMT (mouse mammary tumor virus-polyoma middle tumor-antigen) mouse mammary gland carcinoma model of breast cancer and Met-1 cells derived from this model as tools to study the role of AR in breast cancer progression. AR protein expression was examined in late-stage primary tumors and lung metastases from MMTV-PyMT mice as well as in Met-1 cells by immunohistochemistry (IHC). Sensitivity of Met-1 cells to the AR agonist dihydrotestosterone (DHT) and anti-androgen therapy was examined using cell viability, migration/invasion, and anchorage-independent growth assays. Late-stage primary tumors and lung metastases from MMTV-PyMT mice and Met-1 cells expressed abundant nuclear AR protein, while negative for estrogen and progesterone receptors. Met-1 sensitivity to DHT and AR antagonists demonstrated a reliance on AR for survival, and AR antagonists inhibited invasion and anchorage-independent growth. These data suggest that the MMTV-PyMT model and Met-1 cells may serve as valuable tools for mechanistic studies of the role of AR in disease progression and how anti-androgens affect the tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=85012295463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012295463&partnerID=8YFLogxK

U2 - 10.1007/s12672-017-0285-6

DO - 10.1007/s12672-017-0285-6

M3 - Article

C2 - 28194662

AN - SCOPUS:85012295463

VL - 8

SP - 69

EP - 77

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 2

ER -